Clinical Trials Browser

Adenocarcinoma, Esophageal Neoplasms

NCT03607656 2023-12-18

CHANGE

Phase 2/3 Completed

270 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02661971 2022-07-11

RAMSES/FLOT7

Phase 2/3 Completed

180 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02172976 2020-09-02

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Phase 2/3 Completed

40 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00952029 2020-03-30

Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2/3 Completed

492 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Phase 2/3 Completed

716 enrolled

Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

NCT00384176 2017-04-14

HORIZON III

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01523431 2017-03-30

Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

Phase 2/3 Completed

583 enrolled

Gastrointestinal

Diarrhea, Neutropenia, Colorectal Neoplasms

NCT01204437 2016-02-10

ICE-II

Phase 2/3 Completed

400 enrolled

Breast

Breast Neoplasms

NCT00861094 2015-12-18

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Phase 2/3 Completed

266 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT01829178 2015-05-13

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

Phase 2/3 Completed

30 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

NCT00785421 2015-01-08

PROSPECT

Phase 2/3 Completed

312 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00975897 2013-12-19

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Phase 2/3 Completed

3,240 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00284258 2012-11-02

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Phase 2/3 Completed

426 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

439 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00960284 2012-01-13

PACT-7

Phase 2/3 Completed

102 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

568 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Clinical Trials

NICE

CHANGE

RAMSES/FLOT7

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

HORIZON III

Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

ICE-II

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

PROSPECT

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Docetaxel in Head and Neck Cancer

PACT-7

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma